Scott T. Tagawa

Also affiliated with Presbyterian Hospital, Weill Cornell Medicine

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 51 papers. Top paper: “Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591”.

Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

Journal of Clinical Oncology(2023)10.1200/jco.23.00573

N/A

2.6DataRank · unranked

69 citations

Charlene Thomas, Oliver Sartor, Michael Sun, Judith Stangl‐Kremser, Mahelia Bissassar +10 more

Imaging expression of prostate‐specific membrane antigen and response to PSMA‐targeted β‐emitting radionuclide therapies in metastatic castration‐resistant prostate cancer

The Prostate(2021)10.1002/pros.24104

N/A

1.5DataRank · unranked

27 citations

Muhammad Junaid Niaz, Myrto Skafida, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals

European Journal of Nuclear Medicine and Molecular Imaging(2021)10.1007/s00259-020-05150-w

N/A

0.584DataRank · unranked

48 citations

Sang Gyu Lee, Katerina Jou, Goutam Chakraborty, Myrto Skafida, Scott T. Tagawa +9 more

Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer

The Oncologist(2020)10.1634/theoncologist.2020-0028

N/A

0.550DataRank · unranked

38 citations

Jaspreet S. Batra, Ryan D. Walsh, Marigdalia K. Ramirez‐Fort, Shankar Vallabhajosula, Yuliya Jhanwar +6 more

High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes

Cancer Discovery(2025)10.1158/2159-8290.cd-24-1509

N/A

0.425DataRank · unranked

16 citations

Jamie M. Sperger, Amy K. Taylor, Katharine E. Tippins, Shannon R. Reese, V. Carreño +31 more

Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0446

N/A

0.414DataRank · unranked

8 citations

Natalie Slopen, Hannah D. McManus, Karen A. Autio, Alicia K. Morgans, Lawrence McSwain +24 more

Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5018

N/A

0.360DataRank · unranked

10 citations

Michael Philip Sun, Jones T. Nauseef, Charlene Thomas, Sandra Huicochea Castellanos, Joseph Earl Thomas +12 more

Phase I/II study of 225Ac-J591 plus 177Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5100

N/A

0.269DataRank · unranked

5 citations

Joseph R. Osborne, Peter Gregos, Charlene Thomas, Mahelia Bissassar, Sharon Singh +14 more

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution

European Urology Oncology(2025)10.1016/j.euo.2025.05.014

N/A

0.269DataRank · unranked

5 citations

Marshall A. Diven, Brady Rippon, Christopher E. Barbieri, Jim C. Hu, Douglas S. Scherr +20 more

Ischemic Stroke with Comorbid Cancer Has Specific miRNA‐mRNA Networks in Blood That Vary by Ischemic Stroke Mechanism

Annals of Neurology(2024)10.1002/ana.26997

N/A

0.269DataRank · unranked

5 citations

Babak B. Navi, Fernando Rodríguez, Lisa M. DeAngelis, Mitchell S.V. Elkind, Costantino Iadecola +10 more

Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.158

N/A

0.176DataRank · unranked

1 citations

Justin M. Lebenthal, Jones T. Nauseef, Muhammad Junaid Niaz, Sabrina Guervil, Escarleth Fernandez +10 more

Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.183

N/A

0.165DataRank · unranked

2 citations

Susan Halabi, Joseph D. Schonhoft, Jun Luo, David M. Nanus, Paraskevi Giannakakou +13 more

Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.45

N/A

0.165DataRank · unranked

2 citations

Sukanya Goswami, Muhammad Junaid Niaz, Charlene Thomas, Paul J. Christos, Joseph R. Osborne +10 more

TROP-2 co-expression with androgen receptor splice variants as a new therapeutic target in prostate cancer.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5060

N/A

0.165DataRank · unranked

2 citations

Jamie M. Sperger, Susan F. Slovin, Scott T. Tagawa, Christos E. Kyriakopoulos, Manish Kohli +5 more

The Interplay between Mutagenesis and Extrachromosomal DNA Shapes Urothelial Cancer Evolution

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.05.07.538753

N/A

0.165DataRank · unranked

2 citations

William F. Hooper, Timothy R. Chu, Heather Geiger, Jennifer Shelton, Minita Shah +21 more

PSMA-targeted actinium-225 therapy in metastatic castration-resistant prostate cancer (mCRPC): Baseline and follow-up PSMA PET parameters associated with outcomes.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.5070

N/A

0.104DataRank · unranked

1 citations

Charlene Thomas, Gabriel Raab, Aaron N. Holmes, Tobechukwu Okobi, Andres Ricaurte‐Fajardo +11 more

Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.120

N/A

0.104DataRank · unranked

1 citations

Michael Sun, Jones T. Nauseef, Muhammad Junaid Niaz, Dunya Imad, Paul J. Christos +11 more

Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis

Journal of Stroke and Cerebrovascular Diseases(2022)10.1016/j.jstrokecerebrovasdis.2021.106297

N/A

0DataRank · unranked

3 citations

Stephanie Buchman Rutrick, Natalie M. LeMoss, Kelsey N. Lansdale, Scott T. Tagawa, Hooman Kamel +3 more

Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial

Translational Oncology(2022)10.1016/j.tranon.2022.101593

N/A

0DataRank · unranked

6 citations

Kritika Subramanian, Sandra Huicochea Castellanos, Charlene Thomas, Arindam Roy Choudhury, Brett Muench +4 more

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps216

N/A

0DataRank · unranked

9 citations

Joseph R. Osborne, Matthew C. Dallos, Jones T. Nauseef, Cora N. Sternberg, Peter Gregos +11 more

Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I/II trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.037

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Michael Sun, Oliver Sartor, Sharon Singh, Mahelia Bissassar +15 more

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of 225Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.077

N/A

0DataRank · unranked

2 citations

Charlene Thomas, Benedict Ho, Juana Martinez Zuloaga, Brian D. Gonzalez, Michael Sun +15 more

Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e17007

N/A

0DataRank · unranked

1 citations

Juana Martinez Zuloaga, Kritika Subramanian, Peter Gregos, Mahelia Bissassar, Sharon Singh +13 more

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0754

N/A

0DataRank · unranked

62 citations

Orsetta Quaini, Kei Mizuno, Francesco Orlando, Yari Ciani, Sheng-Yu Ku +23 more

Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-1305

N/A

0DataRank · unranked

54 citations

Kyle T. Helzer, Charlotte N. Stahlfeld, Dawei Jiang, Anupama Singh, Katherine R. Kaufmann +19 more

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men

Scientific Reports(2023)10.1038/s41598-023-35567-w

N/A

0DataRank · unranked

16 citations

J Gil Martínez, Sandra Huicochea Castellanos, Jana Ivanidze, Himanshu Nagar, Sean Nicholson +5 more

Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Quality of Life Research(2023)10.1007/s11136-023-03468-0

N/A

0DataRank · unranked

9 citations

Natalie Slopen, Karen A. Autio, Alicia K. Morgans, Lawrence McSwain, Pedro C. Barata +18 more

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4505

N/A

0DataRank · unranked

21 citations

Jonathan E. Rosenberg, Rana R. McKay, Thomas W. Flaig, Daniel P. Petrylak, Christopher Hoimes +14 more

Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.tps589

N/A

0DataRank · unranked

1 citations

Karla V. Ballman, Scott T. Tagawa, Alan Tan, Bishoy M. Faltas, Arshin Sheybani +11 more

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial

EClinicalMedicine(2024)10.1016/j.eclinm.2024.102862

N/A

0DataRank · unranked

26 citations

Andrei Gafita, Johann S. De Bono, Oliver Sartor, Kim N., Bernd J. Krause +11 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0DataRank · unranked

7 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2024)10.1200/jco.2024.42.16_suppl.5074

N/A

0DataRank · unranked

5 citations

Charlene Thomas, Jones T. Nauseef, Oliver Sartor, Michael Philip Sun, Sandra Huicochea Castellanos +14 more

Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.05.028

N/A

0DataRank · unranked

49 citations

Muhammad Junaid Niaz, Young E. Whang, Arif Sheikh, Charlene Thomas, Paul J. Christos +8 more

Genomic alterations in the YAP/TAZ pathway are associated with stem cell-like castration-resistant prostate cancer

medRxiv(2025)10.1101/2025.07.01.25330467

N/A

0DataRank · unranked

0 citations

Alexander Martinez‐Fundichely, Sandra Cohen, Metin Balaban, Chen Khuan Wong, Weiling Li +26 more

Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

The Prostate(2020)10.1002/pros.24056

N/A

0DataRank · unranked

28 citations

Kenneth J. Pienta, John W. Babich, Neil H. Bander, Jérémie Calais, Peter L. Choyke +11 more

Folate Hydrolase-1 (Folh1) is a Novel Target for Antibody-Based Brachytherapy in Merkel Cell Carcinoma

Skin Health and Disease(2020)10.1002/ski2.9

N/A

0DataRank · unranked

5 citations

Barbara Meier, Kristina Lachance, Sean S. Mahase, Candice D. Church, Muhammad Junaid Niaz +16 more

Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.114

N/A

0DataRank · unranked

24 citations

Joseph R. Osborne, Muhammad Junaid Niaz, Shankar Vallabhajosula, Panagiotis J. Vlachostergios, Charlene Thomas +9 more

A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.07.24.220277

N/A

0DataRank · unranked

13 citations

Sang Gyu Lee, Katerina Jou, Goutam Chakraborty, Myrto Skafida, Scott T. Tagawa +9 more

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5560

N/A

0DataRank · unranked

10 citations

Joseph R. Osborne, Escarleth Fernandez, Charlene Thomas, Muhammad Junaid Niaz, Amy Ciriaco +10 more

Circulating tumor DNA (ctDNA) to detect neuroendocrine prostate cancer genomic and DNA methylation changes.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.8

N/A

0DataRank · unranked

2 citations

Alessandro Romanel, Vincenza Conteduca, Nicola Casiraghi, Michael Sigouros, Gian Marco Franceschini +13 more

AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.184

N/A

0DataRank · unranked

1 citations

Jun Luo, Monika Anand, Emmanuel S. Antonarakis, David M. Nanus, Paraskevi Giannakakou +10 more

Mechanisms of Ischemic Stroke in Patients with Cancer: A Prospective Study

Annals of Neurology(2021)10.1002/ana.26129

N/A

0DataRank · unranked

70 citations

Carla Sherman, Richard Genova, Ryna Mathias, Kelsey N. Lansdale, Natalie M. LeMoss +14 more

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology(2021)10.3389/fonc.2021.630589

N/A

0DataRank · unranked

43 citations

Muhammad Junaid Niaz, Michael Sun, Seyed Ali Mosallaie, Charlene Thomas, Paul J. Christos +6 more

Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

European Urology Open Science(2021)10.1016/j.euros.2021.09.015

N/A

0DataRank · unranked

19 citations

Emmanuel S. Antonarakis, Tina Mayer, Daniel H. Shevrin, Mark N. Stein, Ulka N. Vaishampayan +22 more

Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond

European Urology Focus(2021)10.1016/j.euf.2021.02.006

N/A

0DataRank · unranked

21 citations

Neil H. Bander, Scott T. Tagawa, Jones T. Nauseef

Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5015

N/A

0DataRank · unranked

30 citations

Michael Sun, Oliver Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar +11 more

Liquid-biopsy transcriptomic profiling uncovers molecular mediators of resistance to androgen receptor signaling inhibition in lethal prostate cancer

medRxiv(2021)10.1101/2021.11.01.21265757

N/A

0DataRank · unranked

2 citations

Bob Zimmermann, Giuseppe Galletti, Susan Halabi, Ada Gjyrezi, Qian Yang +16 more

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.5055

N/A

0DataRank · unranked

0 citations

Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg +4 more

Ischemic stroke with cancer: Hematologic and embolic biomarkers and clinical outcomes

Journal of Thrombosis and Haemostasis(2022)10.1111/jth.15779

N/A

0DataRank · unranked

33 citations

Cenai Zhang, Carla Sherman, Richard Genova, Natalie M. LeMoss, Hooman Kamel +9 more

The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer

JNCI Cancer Spectrum(2022)10.1093/jncics/pkac035

N/A

0DataRank · unranked

11 citations

Vaibhav G. Patel, Xiaobo Zhong, Luis A. Pina, Jessica E. Hawley, Emily Lin +17 more